Drug intelligence / Profile preview

ND-10

Development stage: Unknown
Lead developer: Theialife
Modality: Small Molecules
Administration: Oral

Overview

ND-10 is an investigational small molecule drug under development by Theialife Sciences for the treatment of high myopia. It is formulated as an extended-release oral medication. The mechanism of action involves antagonism of adenosine receptors—primarily the A2A subtype—and upregulation of dopamine. This dual action stimulates the synthesis of collagen I and fibronectin in scleral fibroblasts, increasing scleral collagen content that is often depleted in myopic eyes. By targeting these pathways, ND-10 aims to slow the progression of myopia[1][2].

Targets

ADORA2A (Adenosine A₂A Receptor)

Beyond the preview

Go deeper on ND-10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ND-10.

Explore the full profile